Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
McCormick
Adele L
AL
Goodall
Ruth L
RL
Joyce
Aengus
A
Ndembi
Nicaise
N
Chirara
Mike
M
Katundu
Pauline
P
Walker
Sarah
S
Yirrell
David
D
Gilks
Charlie F
CF
Pillay
Deenan
D
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D009154:Mutation / Q000187:drug effects / Q000235:genetics; D019562:Viral Load / Q000187:drug effects; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D004338:Drug Combinations; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine